Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 11/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046669 | 0.89 | KDM5A (0.48) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL18159119 | 0.86 | KDM5A (0.53) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL9204181 | 0.85 | KDM4E (0.45) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16046173 | 0.85 | KDM5A (0.44) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16046333 | 0.85 | KDM5A (0.45) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16050639 | 0.85 | KDM5A (0.52) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16046175 | 0.84 | KDM5A (0.43) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16047855 | 0.83 | KDM5A (0.43) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16077829 | 0.83 | KDM4E (0.51) | KDM5AKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL16046543 | 0.83 | KDM5A (0.50) | KDM5AKDM4CKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3041474-B1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM4C 9/4885KDM4E 12/4885 |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | KDM5A 1/4885KDM4C 7/4885KDM4E 9/4885 |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM1B, DOT1L, EHMT1 | KDM5A 4/4885KDM4C 13/4885KDM4E 27/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM4C 23/4885KDM4E 25/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM4C 9/4885KDM4E 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.